Selank Research Guide: Tuftsin Analog, GABA & Anxiolytic Pathways

What Is Selank?

Selank (widely used research synonym TP-7) is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a stabilized analog of tuftsin, the endogenous immunomodulatory tetrapeptide Thr-Lys-Pro-Arg (the TKPR fragment of the IgG heavy chain). Selank takes that tuftsin core and extends it at the C-terminus with a Pro-Gly-Pro tail, a modification designed to improve metabolic and enzymatic stability and to lengthen duration of action relative to the rapidly degraded parent peptide.

Selank was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as part of a long-running Russian neuro/immuno peptide program (Zozulya, Kost, Kozlovskaya, Myasoedov, Andreeva, Slominsky and colleagues). It is a useful reference compound for laboratory work modeling GABAergic signaling, enkephalin turnover, and tuftsin-derived immunomodulation. Note that essentially all of the published mechanism comes from rodent in-vivo and in-vitro models, and much of it from a single research lineage — independent Western replication is sparse.

Mechanism of Action

Selank's studied mechanism is anxiolytic-leaning and multi-pathway, and — this matters for how the data should be read — it has been characterized almost entirely in rodent and in-vitro models. The reported pathways are mechanistic and preclinical; they are not demonstrated clinical outcomes.

GABAergic Modulation

In rats, intranasal Selank altered the expression of GABA-system genes, including major GABA-receptor subunits, in the frontal cortex, with a strong positive correlation to the effect of GABA itself at one hour (Volkova et al., 2016). That pattern is consistent with Selank acting as an allosteric modulator of the system rather than a direct orthosteric ligand at the GABA site. Related binding work reports that Selank changes the number of GABA specific binding sites without altering receptor affinity.

Enkephalinase Inhibition

Selank dose-dependently inhibits enkephalin-degrading enzymes (enkephalinases) in plasma and serum, which slows the breakdown of endogenous enkephalins — the route most often proposed for its anxiolytic-leaning activity. The two primary papers report figures from two different assays, which is why both are presented here rather than averaged: an IC₅₀ of roughly 15 µM in plasma (Zozulya et al., 2001) and roughly 20 µM in human serum (Kost et al., 2001), in both cases more potent than the reference inhibitors bacitracin and puromycin. The inhibitory activity localizes to the pentapeptide fragment of the molecule.

BDNF / Neurotrophic and Monoamine Signaling

Intranasal Selank regulated Bdnf expression in the rat hippocampus in vivo (Inozemtseva et al., 2008), placing it among peptides studied for neurotrophic gene effects. Preclinical reports also describe normalization of stress-induced changes in serotonin, dopamine and noradrenaline and modulation of serotonin metabolism — described here at the mechanism level, since specific monoamine measurements vary by model.

Immunomodulation (the tuftsin inheritance)

Because Selank is a tuftsin analog, it carries immunomodulatory activity. A single intraperitoneal injection altered the temporal expression of inflammation- and cytokine-related genes — including shifts in C3, Casp1, Il2rg and Xcr1 — in mouse spleen (Kolomin et al., 2014), with reported effects on interferon/IL-6 and Th1/Th2 balance in the broader literature. This is the through-line back to its parent peptide: an immune-active core with an added neuroactive profile.

What the Research Literature Reports

The evidence base for Selank is best described as moderate for mechanism and limited/preclinical for outcomes. Each of the core mechanistic claims below is anchored to real primary literature; what is largely missing is independent human clinical data within the scope of research-grade material. The findings are reported for context, not as a use indication.

Enkephalinase Inhibition

Zozulya et al., Bulletin of Experimental Biology and Medicine, 2001 reported that Selank inhibits enkephalin-degrading enzymes in plasma in a dose-dependent manner (IC₅₀ ~15 µM), more potently than bacitracin and puromycin, and framed this as a possible mechanism of its anxiolytic activity (PMID: 11550013). The companion study, Kost et al., Russian Journal of Bioorganic Chemistry, 2001, showed that both Semax and Selank inhibit the enkephalin-degrading enzymes of human serum (Semax IC₅₀ ~10 µM; Selank IC₅₀ ~20 µM), with the inhibitory activity localized to the pentapeptide fragments.

GABAergic Gene Expression

Volkova et al., Frontiers in Pharmacology, 2016 reported that intranasal Selank (300 µg/kg in the model) altered the expression of genes involved in GABAergic neurotransmission, including major GABA-receptor subunits, in rat frontal cortex — with a strong positive correlation to GABA's own effect at one hour, consistent with allosteric modulation (PMID: 26924987).

BDNF Regulation

Inozemtseva et al., Doklady Biological Sciences, 2008 reported that intranasal administration of Selank regulates BDNF (Bdnf) expression in the rat hippocampus in vivo (PMID: 18841804).

Immunomodulatory Gene Dynamics

Kolomin et al., Molecular Immunology, 2014 reported that, as a tuftsin analog, Selank alters the temporal expression of inflammation-related genes (including C3, Casp1, Il2rg and Xcr1) in mouse spleen after a single intraperitoneal injection, supporting immunomodulatory activity.

Reconstitution & Handling for Research

Selank ships as a lyophilized (freeze-dried) powder and is reconstituted into solution before use in research preparations. The guidance below reflects general peptide-chemistry and USP-grade diluent practice — it is not Selank-validated stability data and should be read as handling practice rather than a shelf-life guarantee.

• Store the powder cold and dry. Keep lyophilized material desiccated and at −20°C (or colder) for long-term storage, where lyophilized peptides typically remain stable on the order of 1–2+ years. Protect from light, moisture, and repeated temperature cycling.
• Equilibrate before opening. Let the sealed vial and the diluent reach room temperature (~18–25°C) before reconstituting — roughly 15–20 minutes from the fridge, 30–40 minutes from −20°C — so condensation does not enter the vial.
• Add diluent gently — do not spray or shake. Run USP-grade bacteriostatic water (sterile water with 0.9% / 9 mg/mL benzyl alcohol) or sterile water slowly down the vial wall, then swirl gently and let the cake dissolve.
• Refrigerate the solution; do not re-freeze. Keep reconstituted Selank at 2–8°C; the benzyl alcohol in bacteriostatic water supports multi-withdrawal use up to ~28 days. Freeze-thaw cycling degrades the peptide, and a notable fraction of solution-phase degradation occurs in the first ~72 hours before settling to a slower rate.
• Treat it as a research reagent. Handle with gloves and clean technique; it is not for human or veterinary use.

Selank vs Semax

Selank is most often compared with Semax, and for good reason: both are synthetic heptapeptides developed at the same Institute of Molecular Genetics (Russian Academy of Sciences), and both share the same C-terminal Pro-Gly-Pro stabilizing tail. But they descend from different parent molecules and are studied for different primary endpoints.

• Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a tuftsin analog, studied with an anxiolytic / GABAergic plus immunomodulatory lean.
• Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-10) fragment analog, studied with a cognition / neurotrophic (BDNF, neuroprotection) lean — and, notably, reported not to stimulate cortisol despite its ACTH lineage.

The overlap is what makes them interesting to study side by side: both inhibit serum enkephalin-degrading enzymes (Kost et al., 2001) and both influence BDNF, which is why they are frequently researched in parallel as complementary, non-overlapping mechanisms rather than substitutes. For the deeper mechanism breakdown of the other half of the pair, see our Semax research guide.

Evaluating Research-Grade Supply

For reproducible work, the supply chain matters as much as the compound. When sourcing Selank for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For a peptide like Selank the COA should report:

• HPLC purity — research-grade heptapeptides should test high purity; check the chromatogram, not just a headline figure.
• Mass-spec confirmation — verifying the measured mass matches the expected ~751.9 g/mol, which confirms you received the full TKPRPGP heptapeptide and not a truncated or mislabeled sequence.
• Salt form and CAS clarity — the free base (CAS 129954-34-3) and the acetate salt carry different CAS numbers and masses, so the COA should state which form the lot is, for catalog and quantification accuracy.
• Batch / lot number and a recent test date linking the COA to your specific vial.

Elytra Labs publishes batch-specific third-party COAs for every research peptide we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret the chromatogram and mass-spec data.

2. Lyophilized Form and Cold-Chain Discipline

Selank should arrive as a lyophilized powder. Keep it cold, dry, and sealed until reconstitution, and reconstitute with clean bacteriostatic water after equilibrating to room temperature. A vendor that ships it properly and documents handling guidance is doing real quality control, not just shipping powder.

Frequently Asked Research Questions

What is Selank?

Selank (research synonym TP-7) is a synthetic heptapeptide, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), and a stabilized analog of the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with a Pro-Gly-Pro tail. Its molecular formula is C₃₃H₅₇N₁₁O₉ (molar mass ~751.9 g/mol; CAS 129954-34-3, free base), and it was developed at the Institute of Molecular Genetics, Russian Academy of Sciences.

How does Selank work in the research models?

Across rodent and in-vitro studies, the reported mechanisms are multi-pathway: it altered GABAergic-neurotransmission gene expression in the frontal cortex consistent with allosteric modulation (Volkova et al., 2016, PMID 26924987); it dose-dependently inhibited enkephalin-degrading enzymes in plasma/serum (IC₅₀ ~15–20 µM; Zozulya et al., 2001, PMID 11550013; Kost et al., 2001); and it regulated hippocampal Bdnf expression (Inozemtseva et al., 2008, PMID 18841804). These are mechanistic, preclinical findings.

How is Selank different from Semax?

Both are Russian heptapeptides sharing a Pro-Gly-Pro tail, but Selank is a tuftsin analog studied for anxiolytic/GABAergic and immune effects, while Semax is an ACTH(4-10) analog studied for cognition and neurotrophic (BDNF) effects. They overlap in that both inhibit serum enkephalinases and both influence BDNF, which is why they are often studied in parallel. See our Semax research guide for the full breakdown.

Is Selank an immunomodulator?

As a tuftsin analog it carries immunomodulatory activity. In mouse spleen a single injection altered the temporal expression of inflammation- and cytokine-related genes such as C3, Casp1, Il2rg and Xcr1 (Kolomin et al., Molecular Immunology, 2014). This is a gene-expression/mechanism observation in a model, not a demonstrated immune outcome.

What does "research-grade" mean for Selank?

It indicates the peptide is intended for laboratory in vitro and animal-model investigation, synthesized in an appropriate facility, and accompanied by analytical documentation (purity, mass spec, salt form, batch records). Selank is not FDA-approved and is not for human or veterinary use; its supporting evidence is largely preclinical and from a single Russian research program. Its registration as an anxiolytic in Russia is regulatory context only, not a claim of efficacy.